Abstract
Carbapenem-resistant Gram-negative bacteria have spread worldwide and constitute a serious public health problem. These organisms are frequently resistant to multiple classes of antimicrobials, limiting our therapeutic options. Agents with potential activity against these multi-drug-resistant bacteria include sulbactam, colistin, tigecycline, aminoglycosides, fosfomycin and, under certain conditions, β-lactams. Clinical experience on the value of each of these agents is still limited. However, in the absence of solid data, various combinations of antibiotics are frequently employed for the treatment of severe infections caused by carbapenem-resistant bacteria.
| Original language | English |
|---|---|
| Pages (from-to) | 28-34 |
| Number of pages | 7 |
| Journal | European Infectious Disease |
| Volume | 6 |
| Issue number | 1 |
| Publication status | Published - 1 Mar 2012 |
Keywords
- Acinetobacter
- Carbapenem-resistant
- Enterobacteriaceae
- Epidemiology
- Multi-drug resistance
- Nosocomial infections
- Pseudomonas
- Resistance mechanisms
- Treatment